Prevalence of EGFR Mutations in epidermoïd Bronchopulmonary Cancers in Réunion Island
NCT ID: NCT04261725
Last Updated: 2023-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
60 participants
OBSERVATIONAL
2020-02-24
2022-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If the incidence of bronchopulmonary cancer is lower in Réunion than in mainland France, the study of histological subtypes appears different: the investigators observe a greater frequency of adenocarcinomas (65% vs 45%), at the expense squamous cell carcinomas. In addition, for adenocarcinomas, the frequency of EGFR type mutations is twice as high (23% vs 11%). Thus, if this rate of EGFR mutations observed in mainland France is very close to those described in all Caucasian populations, that observed in the Reunionese population appears closer to those described in Asian populations, and more particularly the Indian population. This can perhaps be explained by the fact that the population of Reunion is a cosmopolitan and highly mixed race, whose share of Asian origin, mainly Indian and Chinese, is significant.
In clinical practice, INCa recommends carrying out the search for the EGFR mutation for any patient with locally advanced or metastatic lung carcinoma, not small cell and non epidermoid. This restriction to the histology of adenocarcinoma is justified by the low frequency of EGFR mutations for other histological types in Caucasian populations. However, some studies describe significant EGFR mutation rates for epidermoid cancers in Asian populations, particularly in India. Thus, given that a large part of the Réunion population shares Asian origins, the question of the frequency of EGFR mutations among squamous cell carcinomas in Réunion is asked.
The hypothesis of this research is that, given the ethnic characteristics of the Reunionese population, the proportion of bronchopulmonary epidermoid cancers carrying the EGFR mutation is potentially significantly higher than that observed in Caucasian populations, including the French metropolitan population. If this rate of EGFR mutations were high in the Reunion population, it would then be necessary to allow the search for this mutation to be extended to all bronchopulmonary cancers, which will improve their therapeutic management.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiological Study to Assess the Prevalence of Lung Cancer
NCT03976804
Phenotypes Associated With Constitutional EGFR Pathogenic Variants
NCT06562491
A Chart Review Study of Adults With Advanced NSCLC
NCT05207423
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation
NCT06247280
A Prognosis and Predicting Genetic Study of Lung Cancer
NCT03234179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Squamous Cell Lung Cancer
Genetic analysis for searching EGFR mutation
EGFR mutation
Searching the EGFR mutation in pulmonary biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EGFR mutation
Searching the EGFR mutation in pulmonary biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* who is diagnosed with bronchopulmonary squamous cell carcinoma in one of the 2 anatomopathology laboratories at Reunion University Hospital,
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de la Réunion
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michel ANDRE, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de la Réunion
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hosiptalier Universitaire de La Réunion - site Nord
Saint-Denis, , Reunion
Centre Hospitalier niversitaire - site Sud
Saint-Pierre, , Reunion
Clinique Saint Clotilde
Sainte-Clotilde, , Reunion
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017/CHU/18
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.